India, Sept. 12 -- Dr. Reddy's Laboratories, a global pharmaceutical company, has announced the completion of a definitive transaction with Johnson & Johnson, to acquire STUGERON(R) and its locally recognised brands, STUGERON(R) FORTE and STUGERON(R) PLUS, across 18 markets in the APAC and EMEA regions, with India and Vietnam as key markets.

STUGERON(R) contains Cinnarizine, an antihistamine indicated for the treatment of vestibular disturbances and vertigo. With STUGERON(R) already holding first position in the Cinnarizine represented pharmaceutical market (RPM) and ranked second in the anti-vertigo extended represented pharmaceutical market (eRPM) in India, this acquisition presents a strategic opportunity for Dr. Reddy's to expand its...